This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity will review off-label or investigational information. Planners for this activity have no relevant financial relationships with any commercial interests. Other Relationships: BioCryst (DMC) Regeneron (IDMC).Advisory Board/Consultant: Alexion, Novartis, BioCryst.De Castro discloses the following relevant financial relationships: Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.ĭisclosure of relevant financial relationships are as follows: Faculty Educatorsĭr. The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Disclosure StatementĪccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Describe the latest research being presented to better manage PNH and its clinical relevanceĪmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™.Learning ObjectivesĪfter participating in the activity, learners should be better able to: Other members of the care team may also participate. This activity has been designed to meet the educational needs of physicians specializing in hematology, neurology, nephrology, immunology, gastroenterology, pulmonology, and cardiology. Hematologic Malignancies and Cellular Therapyĭuke Hematologic Malignancies Clinic Target Audience This accredited CME activity highlights the latest information about PNH from ASH 2021 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients they may encounter with this rare condition. Supported by an educational grant from Apellis.Įstimated time to complete: 0.25 hours Activity DescriptionĪt ASH 2021, new information and data were presented on paroxysmal nocturnal hemoglobinuria (PNH)-a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |